Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul 17;24(11):1781-4.
doi: 10.1097/QAD.0b013e32833ad8b4.

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Marisa Tungsiripat  1 , Douglas Kitch, Marshall J Glesby, Samir K Gupta, John W Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F Rooney, Judith A Aberg
Affiliations
Randomized Controlled Trial

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

Marisa Tungsiripat et al. AIDS. .

Abstract

Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Notification: Original signed copy will be mailed.

MT: no conflicts

DWK: no conflicts

MJG: no conflicts

SKG: Gilead Sciences: Speaker’s fees, consultant fees, and grant support

JWM: Gilead Sciences: Consultant

Merck: Consultant and grant support

Chimerix: Consultant

RFS Pharmaceuticals: Owns stock options

LM: no conflicts

LJ: no conflicts

BAS: no conflicts

JFR: employee of Gilead Sciences

JAA: Gilead Sciences: Advisory Board, Clinical Trial support, CME sponsored events Honorarium

References

    1. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003. - PubMed
    1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296. - PubMed
    1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids. 1998;12:F51–58. - PubMed
    1. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. Jama. 2003;289:2978–2982. - PubMed
    1. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627. - PubMed

Publication types

MeSH terms

Grants and funding